Insider Trading May 21, 2026 07:35 PM

Director Granot Sells ORMAT Technologies Stock After Completing Rights Exercise

Analysis of recent insider transactions and strong Q1 financial performance for ORA.

By Nina Shah ORA

David Granot, a director at Ormat Technologies, Inc., recently executed several stock transactions involving sales and the acquisition resulting from the exercise of Stock Appreciation Rights (SARs). These activities were reported alongside details regarding his current holdings. Furthermore, recent company reports indicated robust financial results for the first quarter of 2026, with earnings per share surpassing estimates.

Director Granot Sells ORMAT Technologies Stock After Completing Rights Exercise
ORA

Key Points

  • Insider activity involving both sales and SAR exercise acquisitions provide insight into director liquidity.
  • Ormat Technologies reported a substantial beat on Q1 2026 EPS ($1.30 vs $0.91 projected).
  • Q1 2026 revenue of $403.9 million surpassed expectations by over 15%.
  • The company's performance suggests strong operational health in the energy or industrial sector.

David Granot, a director at Ormat Technologies, Inc. (NASDAQ:ORA), completed several stock transactions on May 13, 2025. The activity included selling company shares totaling $69,446, which were transacted at prices ranging from $72.99 to $73.84 per share. This sales action was reported in conjunction with a separate acquisition of 1,315 shares of common stock, valued at $88,815, purchased at a rate of $67.54 per share on the same date.

The sale component involved 950 shares of ORMAT TECHNOLOGIES common stock, which were disposed of in various blocks directly on the open market. This filing serves to amend an earlier report, clarifying certain details regarding share dispositions and correcting previous omissions concerning the exercise of Stock Appreciation Rights (SARs) and related share transactions.

The acquisition of 1,315 shares originated from the exercise of Stock Appreciation Rights that were scheduled to expire in November 2026. Following this exercise event, an additional 1,203 shares were disposed of at $73.84 per share, amounting to a total value of $88,829. This disposition is explicitly stated as representing shares withheld for tax purposes stemming from the SAR exercise.

Following these reported transactions, Mr. Granot's direct holdings in ORMAT TECHNOLOGIES common stock amount to 2,825 shares. In a separate development concerning company valuation, an analysis provided by InvestingPro noted that the stock is currently trading near its 52-week high and appears overvalued when assessed using Fair Value metrics.



Q1 Financial Performance Highlights

In addition to the insider activity report, Ormat Technologies Inc. recently released strong financial results for the first quarter of 2026. These figures indicated that the company surpassed analysts’ expectations across key performance indicators.

  • Earnings Per Share (EPS): The reported EPS reached $1.30, which was notably higher than the anticipated figure of $0.91. This variance represents a significant positive surprise of 42.86%.
  • Revenue: Ormat Technologies generated revenue totaling $403.9 million. This figure exceeded the projected amount of $348.98 million by an increase of 15.74%.

These combined results underscore a solid operational and financial performance for the company during the recent quarter. While the provided context did not detail specific analyst reactions to these figures, both the reported earnings and revenue numbers point toward a positive financial outcome for Ormat Technologies.



Key Takeaways From Recent Activity

The reporting reveals two distinct areas of focus: executive activity and operational performance. The director's transactions highlight specific capital movements involving SAR exercises and stock sales, providing a snapshot into internal share liquidity.

For the broader market, the key points are:

  • Insider Transaction Details: Director David Granot sold 950 shares while simultaneously acquiring 1,315 shares through the exercise of Stock Appreciation Rights (SARs).
  • Strong Financial Beat: The company reported Q1 2026 earnings per share at $1.30, significantly outperforming consensus estimates ($0.91).
  • Revenue Growth Exceeding Expectations: Revenue reached $403.9 million in Q1 2026, representing a 15.74% increase over the anticipated revenue of $348.98 million.

These developments suggest both internal capital management by leadership and strong underlying operational momentum for Ormat Technologies.

Potential Risks and Uncertainties

Several factors, based strictly on the provided data, warrant attention regarding potential risks or uncertainties impacting the company's valuation and stability. These are primarily related to market perception and internal transactions:

  • Valuation Concerns: An analysis indicated that ORMAT TECHNOLOGIES stock is currently trading near its 52-week high and appears overvalued based on Fair Value metrics, suggesting potential pressure from valuation skepticism.
  • Transaction Complexity: The reporting of the director's transactions involves complex mechanisms like Stock Appreciation Rights (SARs) and subsequent tax withholdings, which adds layers of complexity to assessing pure capital flow motives.

The financial sector may monitor how sustained strong earnings translate into long-term valuation support, particularly given the current assessment of overvaluation.

Risks

  • Overvaluation concerns, as indicated by an analysis showing the stock trading near its 52-week high and appearing overvalued based on Fair Value metrics.
  • The complexity of executive share transactions involving SAR exercises and tax withholdings could obscure simple assessment of net capital flow.

More from Insider Trading

Rackspace Technology Executive Offloads Shares to Cover Tax Obligations Amid Stock Surge Jun 4, 2026 Fermi Inc. Executive Unloads $1M in Shares Amid Ongoing Corporate Restructuring Jun 4, 2026 Veracyte Executive Sells Nearly $700K in Shares Amid Product Rollouts and Analyst Upgrades Jun 4, 2026 Veracyte Executive Traces Share Disposition Amid Clinical Milestones and Valuation Scrutiny Jun 4, 2026 Veracyte CFO Executes $177K Stock Sale Amid Clinical Trial Updates and Analyst Revisions Jun 4, 2026